Local drug producer Genovate Biotechnology Co (健亞) yesterday said it plans to invest US$1 million to buy a 1.42 percent stake in China-based PuraPharm Corp (培力) to co-develop botanic drugs aimed at curing central nervous system and metabolic disorders.
PuraPharm is the fourth-largest botanical drug manufacturer in China in terms of drug exports.
The company’s plan to go public in Hong Kong has opened an window for Genovate to subscribe to its shares, Genovate deputy spokesperson Ann Lin (林惠玲) said by telephone.
“Although Genovate does not have experience in developing botanical drugs, the company can offer its expertise in metabolic disorders, such as gout and diabetes, and central nervous system diseases,” she said.
According to data compiled by PuraPharm, the market value of botanic drugs in China was 250 billion yuan (US$41 billion) last year, accounting for 25 percent of China’s drug market, and the figure could grow by a double-digit percentage every year.
First Capital Management Inc (第一金投顧) yesterday said in a note that the cooperation between the two companies is still in its preliminary stage and the deal’s potential sales contribution to Genovate is unclear.
However, it is likely that the two firms will jointly develop biosimilars for treating cancer based on PuraPharm’s strong foundation in botanic drugs, First Capital said.
First Capital forecast Genovate will report 19.91 percent revenue growth of NT$420 million ($US14 million) this year with a profit of NT$59.54 million.
In the first nine months, Genovate saw its revenue increase 11.38 percent year-on-year to NT$304.23 million, while its net income grew to NT$30.05 million in the first six months from NT$17.36 million the previous year.
Genovate’s shares rose 3.77 percent to NT$45.45 yesterday.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure